To evaluate the potential relevance for stroke therapy, mice were systemically treated with roxadustat, a low-molecular weight HIF-PHD inhibitor (HIF-PHI) approved in a number of countries for the treatment of symptomatic anemia associated with chronic kidney disease 38, and semi-targeted GC/MS was applied to determine potential changes in brain metabolism. The gene discussed is PDC; the disease is anemia.